Page 74 - Read Online

Page 6 of 6 Buonfiglioli et al. Hepatoma Res 2018;4:6 I http://dx.doi.org/10.20517/2394-5079.2017.42

8. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
9. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with
hepatitis C virus infection. Hepatology 2016;64:130-7.
10. van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D’Ambrosio R, Pol
S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo
M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HL. Risk of cirrhosis-related complications in patients with advanced fibrosis following
hepatitis C virus eradication. J Hepatol 2017;66:485-93.
11. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus
infection: a systematic review. Ann Intern Med 2017;166:637-48.
12. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of
compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10.
13. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X,
Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol
2016;65:719-26.
14. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti
S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol
2016;65:727-33.
15. Renzulli M, Buonfiglioli F, Conti F, Brocchi S, Serio I, Foschi FG, Caraceni P, Mazzella G, Verucchi G, Golfieri R, Andreone P, Brillanti
S. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related
cirrhosis. Eur Radiol 2018;28:506-13.
16. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct
acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
17. Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, Verlinden W, Brixco C, Decaestecker J, de Galocsy
C, Janssens F, Van Overbeke L, Van Steenkiste C, D’Heygere F, Cool M, Wuyckens K, Nevens F, Robaeys G. The risk of early occurrence
and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated
interferon: a Belgian experience. J Viral Hepat 2017;24:976-81.
18. Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour JF. Hepatocellular carcinoma recurrence
after direct antiviral agent treatment: A European multicentre study. J Hepatol 2017;67:876-8.
19. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack
of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol
2016;65:734-40.
20. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol
2016;65:663-5.
21. Werner JM, Adenugba A, Protzer U. Immune reconstitution after HCV clearance with direct antiviral agents: potential consequences for
patients with HCC? Transplantation 2017;101:904-9.
22. Romano A, Capra F, Piovesan S, Chemello L, Cavalletto L, Anastassopoulos G, Vincenzi V, Scotton P, Panese S, Tempesta D, Gambato M,
Russo FP, Bertin T, Carrara M, Carlotto A, Carolo G, Scroccaro G, Alberti A. Incidence and pattern of “de novo” hepatocellular carcinoma
in HCV patients treated with oral DAAs. Hepatology 2016;64:10A.
23. Reig M, Marino Z, Perello C, Inarrairaegui M, Lens S, Diaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J.
Tumour recurrence after interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a
more aggressive pattern and faster tumour growth. J Hepatol 2017;66:PS-031.
24. Nakao Y, Hashimoto S, Abiru S, Komori A, Yamasaki K, Nagaoka S, Saeki A, Bekki S, Kugiyama Y, Kuroki T, Ito M, Nakao K, Yatsuhashi
H. Rapidly growing, moderately differentiated HCC: a clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy? J
Hepatol 2017; doi: 10.1016/j.jhep.2017.11.011.